Skip Navigation



NDT Advance Access published online on September 28, 2007
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfm589
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
23/2/518    most recent
gfm589v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Waanders, F.
Right arrow Articles by van Goor, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Waanders, F.
Right arrow Articles by van Goor, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Renoprotective effects of the AGE-inhibitor pyridoxamine in experimental chronic allograft nephropathy in rats

Femke Waanders1,2, Else van den Berg1,2, Ryoji Nagai3, Ingrid van Veen2, Gerjan Navis1 and Harry van Goor2

1Department of Nephrology, 2Department of Pathology and Laboratory Medicine, University Medical Centre Groningen, The Netherlands and 3Department of Biochemistry, Kumamoto University, School of Medicine, Kumamoto, Japan

Correspondence and offprint requests to: F. Waanders, MD, University Medical Centre Groningen, Department of Nephrology, Room 40.4.45, P.O. Box 30.001, 9700 RB Groningen, The Netherlands. Email: F.Waanders{at}int.umcg.nl



  Abstract

Background. Advanced glycation end products (AGEs) are involved in diabetic nephropathy (DN). The AGE formation inhibitor pyridoxamine (PM) is renoprotective in DN and in normoglycaemic obese Zucker rats. In chronic allograft nephropathy (CAN), renal AGE accumulation occurs as well.

Methods. To investigate whether inhibition of AGE formation is renoprotective in CAN, we studied the Fisher 344 to Lewis (F–L) allograft rat model of experimental CAN. Fisher to Fisher (F–F) isografts served as controls. Proteinuria, renal function and renal histology of untreated transplanted rats (F–L n = 8, F–F n = 8) were compared to rats receiving PM 2 g/l in drinking water for 20 weeks starting at transplantation (F–L n = 5, F–F n = 10). All rats received cyclosporin A (1.5 mg/kg/day) for 10 days after transplantation to prevent early acute rejection.

Results. Compared to untreated allografts, PM significantly decreased proteinuria (76 ± 18 vs 29 ± 3 mg/day), serum creatinine (130 ± 12 vs 98 ± 5 µmol/l), focal glomerulosclerosis (116 ± 27 vs 16 ± 5 AU), glomerular macrophage influx (5.6 ± 0.6 vs 3.3 ± 1.0), interstitial fibrosis (132 ± 24 vs 76 ± 2 AU) and interstitial macrophage influx (47.0 ± 8.7 vs 15.4 ± 5.0. Moreover, PM significantly ameliorated tubular accumulation of pentosidine, compared to untreated allografts (2.5 ± 0.6 vs 0.3 ± 0.3, all p < 0.05). In the isograft controls, these values did not differ between untreated and PM treated rats.

Conclusion. PM exerts renoprotective effects and decreases renal pentosidine accumulation in experimental CAN, suggesting a detrimental role for renal AGE accumulation in the pathogenesis of renal damage in this non-diabetic model. These results indicate that inhibition of AGE formation might be a useful adjunct therapy to attenuate CAN.

Keywords: advanced glycation end products; chronic allograft nephropathy; kidney transplantation; Maillard reaction; pentosidine; pyridoxamine

Received for publication: 2. 2.07
Accepted in revised form: 2. 8.07


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.